Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole + Sertraline in PTSD
NCT04124614Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Brexpiprazole + Sertraline with Sertraline + Placebo (2 arms). Primary endpoint: Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score at Week 10. Started Oct 2019; status: completed.
02
Drugs
brexpiprazole
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04124614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124614.